Astec LifeSciences Limited

Astec LifeSciences Limited

Astec LifeSciences Limited has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, stating that the regulation is not applicable to the company as its shares are entirely in demat form and no rematerialisation requests were received during the quarter ended 30th September 2026.

Astec LifeSciences Limited

Astec LifeSciences Limited has responded to a notice from the National Stock Exchange of India Limited regarding a significant increase in volume. The company has confirmed compliance with listing regulations and denied any developments requiring mandatory disclosure.

Astec LifeSciences Limited

Astec LifeSciences Limited has observed a significant increase in volume, prompting the exchange to write to the company for a response.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from 1st October, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the Quarter and Half Year ending on 30th September, 2026.

Astec LifeSciences Limited

Astec LifeSciences Limited has responded to a notice from the National Stock Exchange regarding a significant increase in volume, confirming compliance with listing regulations and stating that there are no developments requiring mandatory disclosure.

Astec LifeSciences Limited

Astec LifeSciences Limited has seen a significant increase in trading volume, prompting the exchange to reach out to the company for clarification.

Astec LifeSciences Limited

Astec LifeSciences Limited has responded to a notice from the National Stock Exchange of India Limited regarding significant price movement in the company's shares. The company confirms compliance with listing regulations and denies any developments requiring mandatory disclosure.

Astec LifeSciences Limited

Astec LifeSciences Limited has experienced significant price movement, prompting the NSE to request information from the company to ensure investors have relevant information.

Astec LifeSciences Limited

Astec LifeSciences Limited has responded to a notice from the National Stock Exchange regarding a significant increase in volume, confirming compliance with listing regulations and stating that there are no developments requiring mandatory disclosure.

Astec LifeSciences Limited

Astec LifeSciences Limited has observed a significant increase in volume, prompting the exchange to write to the company for a response.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange regarding 'Adoption of Annual Report 2025-26 by the Shareholders at the AGM held on 31st July, 2026.' The company has adopted its annual report for the financial year 2025-26 and has also re-appointed Mr. Ashok V. Hiremath as a director. The AGM was held through video conferencing and the results of the voting will be declared within 2 working days.

Astec LifeSciences Limited

Astec LifeSciences Limited has held its 32nd Annual General Meeting (AGM) on July 31, 2026, where the company's financial statements for the year ended March 31, 2026, were adopted, and the results of the voting on various resolutions were declared.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange about General Updates, including the outcome of the 32nd Annual General Meeting (AGM) and the adoption of financial statements for the Financial Year ended 31 March, 2026. The AGM was held on 31 July, 2026, and the results of the voting will be declared within 2 working days.

Astec LifeSciences Limited

Astec LifeSciences Limited has announced its Q1 FY27 financial results, reporting a consolidated total income of ₹84.3 crore, a 8.0% decline from ₹91.6 crore in Q1FY26. The company achieved EBITDA breakeven in the quarter compared to an EBITDA loss of ₹10.5 crore in the same period last year, despite lower revenues. Revenue from Enterprise Products grew 42% YoY to ₹51.8 crore in Q1 FY27, compared to ₹36.5 crore in Q1 FY26.

Astec LifeSciences Limited

Astec LifeSciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a loss of Rs. 1,873.82 lakhs before tax and Rs. 1,870.73 lakhs after tax. The company's revenue from operations was Rs. 8,356.43 lakhs, with a total income of Rs. 8,429.17 lakhs. The company has also noted the limited review reports of the statutory auditors, which are with an unmodified opinion.

Astec LifeSciences Limited

Astec LifeSciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, showing a loss of Rs. 1,873.82 lakhs before tax and Rs. 1,870.73 lakhs after tax. The company's revenue from operations was Rs. 8,356.43 lakhs, with a net loss of Rs. 1,861.72 lakhs for the quarter.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on the stock exchange.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 32nd Annual General Meeting (AGM) and the extension of a special window for re-lodging physical share transfer requests. Shiva Texyarn Limited has also published a notice for the extension of a special window for re-lodging physical share transfer requests.

Astec LifeSciences Limited

Astec LifeSciences Limited has informed the Exchange regarding 'Closure of Register of Members and Share Transfer Books' for the purpose of the 32nd Annual General Meeting.